Skip to search formSkip to main contentSkip to account menu

PBI-05204

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

oleandrin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase II clinical trial of novel agent PBI-05204 in patients with metastatic pancreatic adenocarcinoma (mPDA).
698Background: Survival statistics for mPDA are dismal and with limited treatment options novel agents are needed to improve… 
2015
2015
Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer therapy?
Dear Sir: We read with great interest the article “PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of… 
2015
2015
Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer?
Dear Sir: A recent letter to the Editor submitted by Dr. Miguel LopezLazaro and his colleagues provided thoughtful commentary on… 
2011
2011
Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.
3023 Background: PBI-05204 (Oleandrin), a cardiac glycoside, inhibits the α-3 subunit Na-K ATPase pump. Relative expression of… 
2009
2009
A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients.
3537 Background: PBI-05204 contains oleandrin, a cardiac glycoside, which inhibits the α-3 subunit Na-K ATPase pump. Over… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)